カテゴリー： QYResearch, 世界, 医療/バイオ

抗うつ薬のグローバル市場2023年：モノアミンオキシダーゼ、三環系、新薬

◆英語タイトル：Global Antidepressant Medication Market Research Report 2023
	◆商品コード：QYR23MA8671 ◆発行会社（リサーチ会社）：QYResearch ◆発行日：2023年3月 ◆ページ数：88 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル ◆産業分野：医薬品

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD2,900 ⇒換算￥440,800	見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）	USD4,350 ⇒換算￥661,200	見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）	USD5,800 ⇒換算￥881,600	見積依頼/購入/質問フォーム

★QYResearchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

本調査レポートは世界の抗うつ薬市場について調査・分析し、世界の抗うつ薬市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析（モノアミンオキシダーゼ、三環系、新薬）、用途別セグメント分析（病院、医学研究所、診療所、その他）、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Alkermes Plc、AbbVie Inc、Eli Lilly And Company、GlaxoSmithKline, Inc.、Merck KGAA、Pfizer Inc.、Teva Pharmaceutical Industries Ltd. (Actavis Generics)、Takeda Pharmaceutical Limited Company.、AstraZenecaなどが含まれています。世界の抗うつ薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、抗うつ薬市場規模を推定する際に考慮しました。

・抗うつ薬市場の概要
- 製品の定義
- 抗うつ薬のタイプ別セグメント
- 世界の抗うつ薬市場規模：タイプ別分析（モノアミンオキシダーゼ、三環系、新薬）
- 抗うつ薬の用途別セグメント
- 世界の抗うつ薬市場規模：用途別分析（病院、医学研究所、診療所、その他）
- 世界の抗うつ薬市場規模予測（2018年-2029年）
- 抗うつ薬の平均価格推移（2018年-2029年）
- 前提条件と制限事項

・メーカー別競争状況
- メーカー別市場シェア
- 世界の主要メーカー、業界ランキング分析
- メーカー別平均価格
- 抗うつ薬市場の競争状況およびトレンド

・抗うつ薬の地域別市場規模
- 北米の抗うつ薬市場規模（2018年-2029年）
- アメリカの抗うつ薬市場規模（2018年-2029年）
- ヨーロッパの抗うつ薬市場規模（2018年-2029年）
- アジア太平洋の抗うつ薬市場規模（2018年-2029年）
- 中国の抗うつ薬市場規模（2018年-2029年）
- 日本の抗うつ薬市場規模（2018年-2029年）
- 韓国の抗うつ薬市場規模（2018年-2029年）
- インドの抗うつ薬市場規模（2018年-2029年）
- オーストラリアの抗うつ薬市場規模（2018年-2029年）
- 中南米の抗うつ薬市場規模（2018年-2029年）
- 中東・アフリカの抗うつ薬市場規模（2018年-2029年）

・タイプ別セグメント：モノアミンオキシダーゼ、三環系、新薬
- 世界の抗うつ薬のタイプ別販売量（2018年-2023年）
- 世界の抗うつ薬のタイプ別売上（2018年-2023年）
- 世界の抗うつ薬のタイプ別価格

・用途別セグメント：病院、医学研究所、診療所、その他
- 世界の抗うつ薬の用途別販売量（2018年-2023年）
- 世界の抗うつ薬の用途別売上（2018年-2023年）
- 世界の抗うつ薬の用途別価格

・主要企業のプロファイル：企業情報、事業概要、売上、製品ポートフォリオ、動向
Alkermes Plc、AbbVie Inc、Eli Lilly And Company、GlaxoSmithKline, Inc.、Merck KGAA、Pfizer Inc.、Teva Pharmaceutical Industries Ltd. (Actavis Generics)、Takeda Pharmaceutical Limited Company.、AstraZeneca

・産業チェーンと販売チャネルの分析
- 抗うつ薬産業チェーン分析
- 抗うつ薬の主要原材料
- 抗うつ薬の販売チャネル
- 抗うつ薬のディストリビューター
- 抗うつ薬の主要顧客

・抗うつ薬市場ダイナミクス
- 抗うつ薬の業界動向
- 抗うつ薬市場の成長ドライバ、課題、阻害要因

・調査成果および結論

・調査方法とデータソース

Highlights
The global Antidepressant Medication market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Antidepressant Medication is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Antidepressant Medication is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Antidepressant Medication include Alkermes Plc, AbbVie Inc, Eli Lilly And Company, GlaxoSmithKline, Inc., Merck KGAA, Pfizer Inc., Teva Pharmaceutical Industries Ltd. (Actavis Generics), Takeda Pharmaceutical Limited Company. and AstraZeneca, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Antidepressant Medication, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antidepressant Medication.
The Antidepressant Medication market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Antidepressant Medication market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antidepressant Medication manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Alkermes Plc
AbbVie Inc
Eli Lilly And Company
GlaxoSmithKline, Inc.
Merck KGAA
Pfizer Inc.
Teva Pharmaceutical Industries Ltd. (Actavis Generics)
Takeda Pharmaceutical Limited Company.
AstraZeneca
Segment by Type
Monoamine Oxidase
Tricyclic
New Drugs
Segment by Application
Hospital
Institute of Medicine
Clinic
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Antidepressant Medication manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Antidepressant Medication in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Antidepressant Medication Market Overview
1.1 Product Overview and Scope of Antidepressant Medication
1.2 Antidepressant Medication Segment by Type
1.2.1 Global Antidepressant Medication Market Value Comparison by Type (2023-2029)
1.2.2 Monoamine Oxidase
1.2.3 Tricyclic
1.2.4 New Drugs
1.3 Antidepressant Medication Segment by Application
1.3.1 Global Antidepressant Medication Market Value by Application: (2023-2029)
1.3.2 Hospital
1.3.3 Institute of Medicine
1.3.4 Clinic
1.3.5 Others
1.4 Global Antidepressant Medication Market Size Estimates and Forecasts
1.4.1 Global Antidepressant Medication Revenue 2018-2029
1.4.2 Global Antidepressant Medication Sales 2018-2029
1.4.3 Global Antidepressant Medication Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Antidepressant Medication Market Competition by Manufacturers
2.1 Global Antidepressant Medication Sales Market Share by Manufacturers (2018-2023)
2.2 Global Antidepressant Medication Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Antidepressant Medication Average Price by Manufacturers (2018-2023)
2.4 Global Antidepressant Medication Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Antidepressant Medication, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antidepressant Medication, Product Type & Application
2.7 Antidepressant Medication Market Competitive Situation and Trends
2.7.1 Antidepressant Medication Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Antidepressant Medication Players Market Share by Revenue
2.7.3 Global Antidepressant Medication Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Antidepressant Medication Retrospective Market Scenario by Region
3.1 Global Antidepressant Medication Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Antidepressant Medication Global Antidepressant Medication Sales by Region: 2018-2029
3.2.1 Global Antidepressant Medication Sales by Region: 2018-2023
3.2.2 Global Antidepressant Medication Sales by Region: 2024-2029
3.3 Global Antidepressant Medication Global Antidepressant Medication Revenue by Region: 2018-2029
3.3.1 Global Antidepressant Medication Revenue by Region: 2018-2023
3.3.2 Global Antidepressant Medication Revenue by Region: 2024-2029
3.4 North America Antidepressant Medication Market Facts & Figures by Country
3.4.1 North America Antidepressant Medication Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Antidepressant Medication Sales by Country (2018-2029)
3.4.3 North America Antidepressant Medication Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Antidepressant Medication Market Facts & Figures by Country
3.5.1 Europe Antidepressant Medication Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Antidepressant Medication Sales by Country (2018-2029)
3.5.3 Europe Antidepressant Medication Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antidepressant Medication Market Facts & Figures by Country
3.6.1 Asia Pacific Antidepressant Medication Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Antidepressant Medication Sales by Country (2018-2029)
3.6.3 Asia Pacific Antidepressant Medication Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Antidepressant Medication Market Facts & Figures by Country
3.7.1 Latin America Antidepressant Medication Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Antidepressant Medication Sales by Country (2018-2029)
3.7.3 Latin America Antidepressant Medication Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Antidepressant Medication Market Facts & Figures by Country
3.8.1 Middle East and Africa Antidepressant Medication Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Antidepressant Medication Sales by Country (2018-2029)
3.8.3 Middle East and Africa Antidepressant Medication Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antidepressant Medication Sales by Type (2018-2029)
4.1.1 Global Antidepressant Medication Sales by Type (2018-2023)
4.1.2 Global Antidepressant Medication Sales by Type (2024-2029)
4.1.3 Global Antidepressant Medication Sales Market Share by Type (2018-2029)
4.2 Global Antidepressant Medication Revenue by Type (2018-2029)
4.2.1 Global Antidepressant Medication Revenue by Type (2018-2023)
4.2.2 Global Antidepressant Medication Revenue by Type (2024-2029)
4.2.3 Global Antidepressant Medication Revenue Market Share by Type (2018-2029)
4.3 Global Antidepressant Medication Price by Type (2018-2029)
5 Segment by Application
5.1 Global Antidepressant Medication Sales by Application (2018-2029)
5.1.1 Global Antidepressant Medication Sales by Application (2018-2023)
5.1.2 Global Antidepressant Medication Sales by Application (2024-2029)
5.1.3 Global Antidepressant Medication Sales Market Share by Application (2018-2029)
5.2 Global Antidepressant Medication Revenue by Application (2018-2029)
5.2.1 Global Antidepressant Medication Revenue by Application (2018-2023)
5.2.2 Global Antidepressant Medication Revenue by Application (2024-2029)
5.2.3 Global Antidepressant Medication Revenue Market Share by Application (2018-2029)
5.3 Global Antidepressant Medication Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Alkermes Plc
6.1.1 Alkermes Plc Corporation Information
6.1.2 Alkermes Plc Description and Business Overview
6.1.3 Alkermes Plc Antidepressant Medication Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Alkermes Plc Antidepressant Medication Product Portfolio
6.1.5 Alkermes Plc Recent Developments/Updates
6.2 AbbVie Inc
6.2.1 AbbVie Inc Corporation Information
6.2.2 AbbVie Inc Description and Business Overview
6.2.3 AbbVie Inc Antidepressant Medication Sales, Revenue and Gross Margin (2018-2023)
6.2.4 AbbVie Inc Antidepressant Medication Product Portfolio
6.2.5 AbbVie Inc Recent Developments/Updates
6.3 Eli Lilly And Company
6.3.1 Eli Lilly And Company Corporation Information
6.3.2 Eli Lilly And Company Description and Business Overview
6.3.3 Eli Lilly And Company Antidepressant Medication Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Eli Lilly And Company Antidepressant Medication Product Portfolio
6.3.5 Eli Lilly And Company Recent Developments/Updates
6.4 GlaxoSmithKline, Inc.
6.4.1 GlaxoSmithKline, Inc. Corporation Information
6.4.2 GlaxoSmithKline, Inc. Description and Business Overview
6.4.3 GlaxoSmithKline, Inc. Antidepressant Medication Sales, Revenue and Gross Margin (2018-2023)
6.4.4 GlaxoSmithKline, Inc. Antidepressant Medication Product Portfolio
6.4.5 GlaxoSmithKline, Inc. Recent Developments/Updates
6.5 Merck KGAA
6.5.1 Merck KGAA Corporation Information
6.5.2 Merck KGAA Description and Business Overview
6.5.3 Merck KGAA Antidepressant Medication Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Merck KGAA Antidepressant Medication Product Portfolio
6.5.5 Merck KGAA Recent Developments/Updates
6.6 Pfizer Inc.
6.6.1 Pfizer Inc. Corporation Information
6.6.2 Pfizer Inc. Description and Business Overview
6.6.3 Pfizer Inc. Antidepressant Medication Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Pfizer Inc. Antidepressant Medication Product Portfolio
6.6.5 Pfizer Inc. Recent Developments/Updates
6.7 Teva Pharmaceutical Industries Ltd. (Actavis Generics)
6.6.1 Teva Pharmaceutical Industries Ltd. (Actavis Generics) Corporation Information
6.6.2 Teva Pharmaceutical Industries Ltd. (Actavis Generics) Description and Business Overview
6.6.3 Teva Pharmaceutical Industries Ltd. (Actavis Generics) Antidepressant Medication Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Teva Pharmaceutical Industries Ltd. (Actavis Generics) Antidepressant Medication Product Portfolio
6.7.5 Teva Pharmaceutical Industries Ltd. (Actavis Generics) Recent Developments/Updates
6.8 Takeda Pharmaceutical Limited Company.
6.8.1 Takeda Pharmaceutical Limited Company. Corporation Information
6.8.2 Takeda Pharmaceutical Limited Company. Description and Business Overview
6.8.3 Takeda Pharmaceutical Limited Company. Antidepressant Medication Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Takeda Pharmaceutical Limited Company. Antidepressant Medication Product Portfolio
6.8.5 Takeda Pharmaceutical Limited Company. Recent Developments/Updates
6.9 AstraZeneca
6.9.1 AstraZeneca Corporation Information
6.9.2 AstraZeneca Description and Business Overview
6.9.3 AstraZeneca Antidepressant Medication Sales, Revenue and Gross Margin (2018-2023)
6.9.4 AstraZeneca Antidepressant Medication Product Portfolio
6.9.5 AstraZeneca Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antidepressant Medication Industry Chain Analysis
7.2 Antidepressant Medication Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antidepressant Medication Production Mode & Process
7.4 Antidepressant Medication Sales and Marketing
7.4.1 Antidepressant Medication Sales Channels
7.4.2 Antidepressant Medication Distributors
7.5 Antidepressant Medication Customers
8 Antidepressant Medication Market Dynamics
8.1 Antidepressant Medication Industry Trends
8.2 Antidepressant Medication Market Drivers
8.3 Antidepressant Medication Market Challenges
8.4 Antidepressant Medication Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 抗うつ薬のグローバル市場2023年：モノアミンオキシダーゼ、三環系、新薬(Global Antidepressant Medication Market Research Report 2023)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

抗うつ薬のグローバル市場2023年：モノアミンオキシダーゼ、三環系、新薬

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp